Objective Adalimumab, a fully human, anti–tumor necrosis factor monoclonal antibody, was
evaluated for its safety and efficacy compared with placebo in the treatment of active …

Background Effective new therapies are needed for rheumatoid arthritis. Current therapies
target the products of activated macrophages; however, T cells also have an important role in …

Objective To determine the clinical efficacy, safety, and immunogenicity of abatacept (CTLA‐4Ig),
a selective costimulation modulator, in patients with rheumatoid arthritis (RA) that has …

Objective. There is no effective treatment for patients with primary Sjögren’s syndrome (SS).
Since tumor necrosis factor (TNF) could be a key element in the pathogenesis of primary SS, …

Patients with Sjögren's syndrome (SS) suffer from deficient secretion of saliva due to an
autoimmune destruction of salivary glands, however, glandular dysfunction also occurs without …

This open-label, phase I/II study investigated the safety and efficacy of epratuzumab, a
humanised anti-CD22 monoclonal antibody, in the treatment of patients with active primary …

Objectives: To evaluate the safety and efficacy of adding ciclosporin A (CSA) to the
treatment of patients with psoriatic arthritis (PsA) demonstrating an incomplete response to …

Salivary glands are involved in secretion of saliva, which is known to participate in the
protection and hydratation of mucosal structures within the oral cavity, oropharynx and …

Objectives: This study aimed to describe the epidemiology of ankylosing spondylitis (AS) in
rheumatology practice at the beginning of the anti-TNF (tumour necrosis factor) era, and to …

Background To develop preliminary classification criteria for the cryoglobulinaemic syndrome
or cryoglobulinaemic vasculitis (CV). Methods Study part I developed a questionnaire for …